Aripiprazole Zentiva

Nchi: Umoja wa Ulaya

Lugha: Kiingereza

Chanzo: EMA (European Medicines Agency)

Nunua Sasa

Taarifa za kipeperushi Taarifa za kipeperushi (PIL)
23-02-2024
Tabia za bidhaa Tabia za bidhaa (SPC)
23-02-2024

Viambatanisho vya kazi:

aripiprazole

Inapatikana kutoka:

Zentiva, k.s.

ATC kanuni:

N05AX12

INN (Jina la Kimataifa):

aripiprazole

Kundi la matibabu:

Psycholeptics

Eneo la matibabu:

Schizophrenia; Bipolar Disorder

Matibabu dalili:

Aripiprazole Zentiva is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.Aripiprazole Zentiva is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.Aripiprazole Zentiva is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.

Bidhaa muhtasari:

Revision: 9

Idhini hali ya:

Authorised

Idhini ya tarehe:

2015-06-25

Taarifa za kipeperushi

                                75
B. PACKAGE LEAFLET
76
PACKAGE LEAFLET: INFORMATION FOR THE USER
ARIPIPRAZOLE ZENTIVA 5 MG TABLETS
ARIPIPRAZOLE ZENTIVA 10 MG TABLETS
ARIPIPRAZOLE ZENTIVA 15 MG TABLETS
ARIPIPRAZOLE ZENTIVA 30 MG TABLETS
aripiprazole
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Aripiprazole Zentiva is and what it is used for
2.
What you need to know before you take Aripiprazole Zentiva
3.
How to take Aripiprazole Zentiva
4.
Possible side effects
5.
How to store Aripiprazole Zentiva
6.
Contents of the pack and other information
1.
WHAT ARIPIPRAZOLE ZENTIVA IS AND WHAT IT IS USED FOR
Aripiprazole Zentiva contains the active substance aripiprazole and
belongs to a group of medicines
called antipsychotics.
It is used to treat adults and adolescents aged 15 years and older who
suffer from a disease
characterised by symptoms such as hearing, seeing or sensing things
which are not there,
suspiciousness, mistaken beliefs, incoherent speech and behaviour and
emotional flatness. People with
this condition may also feel depressed, guilty, anxious or tense.
Aripiprazole Zentiva is used to treat adults and adolescents aged 13
years and older who suffer from
a condition with symptoms such as feeling “high”, having excessive
amounts of energy, needing much
less sleep than usual, talking very quickly with racing ideas and
sometimes severe irritability. In adults
it also prevents this condition from returning in patients who have
responded to the treatment with
Aripiprazole Zentiva.
2.
WHAT YOU NEED TO KNOW BEFORE YOU T
                                
                                Soma hati kamili
                                
                            

Tabia za bidhaa

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Aripiprazole Zentiva 5 mg tablets
Aripiprazole Zentiva 10 mg tablets
Aripiprazole Zentiva 15 mg tablets
Aripiprazole Zentiva 30 mg tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Aripiprazole Zentiva 5 mg tablets
Each tablet contains 5 mg of aripiprazole.
Excipient with known effect
Each tablet contains 33 mg of lactose (as monohydrate).
Aripiprazole Zentiva 10 mg tablets
Each tablet contains 10 mg of aripiprazole.
Excipient with known effect
Each tablet contains 66 mg of lactose (as monohydrate).
Aripiprazole Zentiva 15 mg tablets
Each tablet contains 15 mg of aripiprazole.
Excipient with known effect
Each tablet contains 99 mg of lactose (as monohydrate).
Aripiprazole Zentiva 30 mg tablets
Each tablet contains 30 mg of aripiprazole.
Excipient with known effect
Each tablet contains 198 mg of lactose (as monohydrate).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablet
Aripiprazole Zentiva 5 mg tablets
White to off-white round flat bevel edged uncoated tablets with
‘5’ debossed on one side and plain
on the other side with diameter approx. 6 mm.
3
Aripiprazole Zentiva 10 mg tablets
White to off-white round uncoated tablets with ‘10’ debossed on
one side and snap tab breakline
on the other side with diameter approx. 8 mm.
The score line is not intended for breaking the tablet.
Aripiprazole Zentiva 15 mg tablets
White to off-white round flat bevel edged uncoated tablets with
‘15’ debossed on one side and plain
on the other side with diameter approx. 8.8 mm.
Aripiprazole Zentiva 30 mg tablets
White to off-white capsule shaped uncoated tablets with ‘30’
debossed on one side and snap tab
breakline on the other side with dimensions approx. 15.5 x 8 mm.
The score line is not intended for breaking the tablet.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Aripiprazole Zentiva is indicated for the treatment of schizophrenia
in adults and in adolescents aged
15 years and older.
Aripiprazole Ze
                                
                                Soma hati kamili
                                
                            

Nyaraka katika lugha zingine

Taarifa za kipeperushi Taarifa za kipeperushi Kibulgaria 23-02-2024
Tabia za bidhaa Tabia za bidhaa Kibulgaria 23-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kibulgaria 30-07-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kihispania 23-02-2024
Tabia za bidhaa Tabia za bidhaa Kihispania 23-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihispania 30-07-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kicheki 23-02-2024
Tabia za bidhaa Tabia za bidhaa Kicheki 23-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kicheki 30-07-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kidenmaki 23-02-2024
Tabia za bidhaa Tabia za bidhaa Kidenmaki 23-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kidenmaki 30-07-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kijerumani 23-02-2024
Tabia za bidhaa Tabia za bidhaa Kijerumani 23-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kijerumani 30-07-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kiestonia 23-02-2024
Tabia za bidhaa Tabia za bidhaa Kiestonia 23-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiestonia 30-07-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kigiriki 23-02-2024
Tabia za bidhaa Tabia za bidhaa Kigiriki 23-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kigiriki 30-07-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kifaransa 23-02-2024
Tabia za bidhaa Tabia za bidhaa Kifaransa 23-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifaransa 30-07-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kiitaliano 23-02-2024
Tabia za bidhaa Tabia za bidhaa Kiitaliano 23-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiitaliano 30-07-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kilatvia 23-02-2024
Tabia za bidhaa Tabia za bidhaa Kilatvia 23-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilatvia 30-07-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kilithuania 23-02-2024
Tabia za bidhaa Tabia za bidhaa Kilithuania 23-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilithuania 30-07-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kihungari 23-02-2024
Tabia za bidhaa Tabia za bidhaa Kihungari 23-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihungari 30-07-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kimalta 23-02-2024
Tabia za bidhaa Tabia za bidhaa Kimalta 23-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kimalta 30-07-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kiholanzi 23-02-2024
Tabia za bidhaa Tabia za bidhaa Kiholanzi 23-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiholanzi 30-07-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kipolandi 23-02-2024
Tabia za bidhaa Tabia za bidhaa Kipolandi 23-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kipolandi 30-07-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kireno 23-02-2024
Tabia za bidhaa Tabia za bidhaa Kireno 23-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kireno 30-07-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kiromania 23-02-2024
Tabia za bidhaa Tabia za bidhaa Kiromania 23-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiromania 30-07-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kislovakia 23-02-2024
Tabia za bidhaa Tabia za bidhaa Kislovakia 23-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovakia 30-07-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kislovenia 23-02-2024
Tabia za bidhaa Tabia za bidhaa Kislovenia 23-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovenia 30-07-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kifinlandi 23-02-2024
Tabia za bidhaa Tabia za bidhaa Kifinlandi 23-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifinlandi 30-07-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kiswidi 23-02-2024
Tabia za bidhaa Tabia za bidhaa Kiswidi 23-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiswidi 30-07-2015
Taarifa za kipeperushi Taarifa za kipeperushi Kinorwe 23-02-2024
Tabia za bidhaa Tabia za bidhaa Kinorwe 23-02-2024
Taarifa za kipeperushi Taarifa za kipeperushi Kiaisilandi 23-02-2024
Tabia za bidhaa Tabia za bidhaa Kiaisilandi 23-02-2024
Taarifa za kipeperushi Taarifa za kipeperushi Kroeshia 23-02-2024
Tabia za bidhaa Tabia za bidhaa Kroeshia 23-02-2024
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kroeshia 30-07-2015

Tafuta arifu zinazohusiana na bidhaa hii